Urinary Incontinence,Stress
Conditions
Brief summary
Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter in women
Detailed description
This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive) in women.
Interventions
Implantation of the device
Sponsors
UroMems SAS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged \>18 years old * Female patient * Cognitively able and willing to sign an informed consent * Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months * Use of medically acceptable contraception, if of childbearing potential * Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints * Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator * Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator * Life expectancy ≥ 5 years as assessed by the investigator * Affiliated with an appropriate social security system * Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, ACT, etc. (excluding other AUS devices) * Negative urine culture prior to the procedure * Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests * Clinically insignificant post-void residual (PVR) urine defined as \< 50 ml and/or no greater than 10% of the voided volume * Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary
Exclusion criteria
* Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months * Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing her from giving her consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn her consent) * Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions * Pregnant patient, or patient planning pregnancy during the study duration * Patient presenting one or several contraindications of the device * Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes * Known allergy to UroMems eAUS implantable components * History of pelvic irradiation (external beam therapy or brachytherapy) * Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of \>12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of \>9% (75 mmol/mol) over the preceding 3 months * History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value \>70 * Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured * Previous AUS implant * Currently has another Active Implantable Medical Device (AIMD) implanted * Urge incontinence, mixed incontinence (MI) with a predominant urgency component * Overflow urinary incontinence * Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods * Abnormal or poor bladder compliance defined as being \<30 ml/ cm H2O * Bladder neck or urethral stricture that may require any long-term instrumental treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of explants and revisions at 6 months after device activation | 6 months after device activation | Rate of explants and revisions |
| Rate of device activation successes | 5 weeks after device implantation | Rate of device activation successes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with 50% reduction or greater in 24-hour pad weight test | 90, 185 days and annually up to 5-years after activation | Number of subjects with 50% reduction or greater in 24-hour pad weight test |
| Number of subjects with 75% reduction or greater in 24-hour pad weight test | 90, 185 days and annually up to 5-years after activation | Number of subjects with 75% reduction or greater in 24-hour pad weight test |
| 3-day bladder diary | at baseline, at device activation, and 90-days, 185-days and annually up to 5-years after activation | Bladder diary will be filled in during 3 consecutive days |
| General quality of life questionnaire | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | General quality of life questionnaire |
| Disease specific questionnaire (level of incontinence) | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | Disease specific questionnaire (level of incontinence) |
| Disease specific questionnaire (symptoms and quality of life) | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | Disease specific questionnaire (symptoms and quality of life) |
| Disease specific questionnaire (sexual activity) | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | Disease specific questionnaire (sexual activity) |
| Disease specific questionnaire (quality of life) | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | Disease specific questionnaire (quality of life) |
| Disease specific questionnaire (type of incontinence) | at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation | Disease specific questionnaire (type of incontinence) |
| Post void residuals | Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation | Post void residuals will be measured to assess the bladder function |
| Patient satisfaction | 5 weeks after device implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation | Patient satisfaction questionnaire |
| Physician satisfaction questionnaire | Within 45 days after baseline (device implantation), 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation | Questionnaire to assess the physician satisfaction regarding the procedure and the device |
| Rate of adverse events | Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation | All categories: serious/not serious events and device- and procedure-related effects |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOREmmanuel Chartier-Kastler
Groupe Hospitalier Pitié-Salpêtrière
Outcome results
None listed